GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mustang Bio Inc (NAS:MBIO) » Definitions » EV-to-FCF

Mustang Bio (Mustang Bio) EV-to-FCF

: -0.01 (As of Today)
View and export this data going back to 2017. Start your Free Trial

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Mustang Bio's Enterprise Value is $0.25 Mil. Mustang Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-49.48 Mil. Therefore, Mustang Bio's EV-to-FCF for today is -0.01.

The historical rank and industry rank for Mustang Bio's EV-to-FCF or its related term are showing as below:

MBIO' s EV-to-FCF Range Over the Past 10 Years
Min: -4.73   Med: -1.4   Max: 1.7
Current: -0.01

During the past 9 years, the highest EV-to-FCF of Mustang Bio was 1.70. The lowest was -4.73. And the median was -1.40.

MBIO's EV-to-FCF is ranked worse than
100% of 386 companies
in the Biotechnology industry
Industry Median: 4.39 vs MBIO: -0.01

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-18), Mustang Bio's stock price is $0.3701. Mustang Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.000. Therefore, Mustang Bio's PE Ratio for today is At Loss.


Mustang Bio EV-to-FCF Historical Data

The historical data trend for Mustang Bio's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mustang Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.17 -4.22 -0.83 0.03 -0.18

Mustang Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 -0.20 -0.60 -0.18 -0.18

Competitive Comparison

For the Biotechnology subindustry, Mustang Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mustang Bio EV-to-FCF Distribution

For the Biotechnology industry and Healthcare sector, Mustang Bio's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Mustang Bio's EV-to-FCF falls into.



Mustang Bio EV-to-FCF Calculation

Mustang Bio's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=0.254/-49.477
=-0.01

Mustang Bio's current Enterprise Value is $0.25 Mil.
Mustang Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-49.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mustang Bio  (NAS:MBIO) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Mustang Bio's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.3701/-6.000
=At Loss

Mustang Bio's share price for today is $0.3701.
Mustang Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Mustang Bio EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Mustang Bio's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Mustang Bio (Mustang Bio) Business Description

Traded in Other Exchanges
N/A
Address
377 Plantation Street, Worcester, MA, USA, 01605
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors.
Executives
Fortress Biotech, Inc. 10 percent owner 1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Rosenwald Lindsay A Md director 375 PARK AVE, NEW YORK NY 10152
Manuel Md Litchman director, officer: President and CEO 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10017
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Brian Achenbach officer: SVP, Fin. & Corp. Controller 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014
Neil Herskowitz director 2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Adam J. Chill director 24 NEW ENGLAND EXECUTIVE PARK, SUITE 105, BURLINGTON MA 01803
Michael S Weiss director 750 LEXINGTON AVE, NEW YORK NY 10022
Michael J Zelefsky director
David J Horin officer: Interim CFO 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020

Mustang Bio (Mustang Bio) Headlines

From GuruFocus

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

By Stock market mentor Stock market mentor 01-17-2023